Showing 43,441 - 43,460 results of 112,403 for search '(( 5 ((ppm decrease) OR (a decrease)) ) OR ( a ((fold decrease) OR (point decrease)) ))', query time: 1.63s Refine Results
  1. 43441

    Adipose-derived stem cells attenuate pulmonary microvascular hyperpermeability after smoke inhalation by Koji Ihara (4495504)

    Published 2017
    “…Sheep were randomly allocated to two groups: 1) ASCs: infused with 200 million of ASCs in 200mL of PlasmaLyteA starting 1 hours post-injury, n = 5; 2) control, treated with 200mL of PlasmaLyteA in a similar pattern, n = 5.…”
  2. 43442

    A 15-gene classifier can predict radiation dose levels in mice. by Joseph Lucas (104191)

    Published 2014
    “…While IGH-6 expression decreased in response to irradiation, LOXL1 expression increased promptly and CDKN1A was a late responsive gene.…”
  3. 43443

    A Hypomorphic Lsd1 Allele Results in Heart Development Defects in Mice by Thomas B. Nicholson (406800)

    Published 2013
    “…While there is evidence that Lsd1-interacting proteins regulate the activity and specificity of Lsd1, the significance and roles of such interactions in developmental processes remain largely unknown. Here we describe a hypomorphic Lsd1 allele that contains two point mutations in the tower domain, resulting in a protein with reduced interaction with known binding partners and decreased enzymatic activity. …”
  4. 43444

    The kinetics of the linear component affect the peak frequency of a bell shaped response. by Patrick A. Fletcher (583336)

    Published 2014
    “…(<b>B</b>) The corresponding bell-shaped responses have a peak that shifts to the right accordingly. (<b>C</b>) Duration compensation: increasing τ<sub>a</sub> shifts the response in </a><a><sub>on,∞</sub> and its K crossing point to the right. …”
  5. 43445
  6. 43446
  7. 43447

    Image1_LIT01-196, a Metabolically Stable Apelin-17 Analog, Normalizes Blood Pressure in Hypertensive DOCA-Salt Rats via a NO Synthase-dependent Mechanism.pdf by Adrien Flahault (2602345)

    Published 2021
    “…LIT01-196 behaves as a potent full agonist for the apelin receptor and has an in vivo half-life in the bloodstream of 28 min after intravenous (i.v.) and 156 min after subcutaneous (s.c.) administrations in conscious normotensive rats. …”
  8. 43448

    Image1_LIT01-196, a Metabolically Stable Apelin-17 Analog, Normalizes Blood Pressure in Hypertensive DOCA-Salt Rats via a NO Synthase-dependent Mechanism.pdf by Adrien Flahault (2602345)

    Published 2021
    “…LIT01-196 behaves as a potent full agonist for the apelin receptor and has an in vivo half-life in the bloodstream of 28 min after intravenous (i.v.) and 156 min after subcutaneous (s.c.) administrations in conscious normotensive rats. …”
  9. 43449

    Image2_LIT01-196, a Metabolically Stable Apelin-17 Analog, Normalizes Blood Pressure in Hypertensive DOCA-Salt Rats via a NO Synthase-dependent Mechanism.pdf by Adrien Flahault (2602345)

    Published 2021
    “…LIT01-196 behaves as a potent full agonist for the apelin receptor and has an in vivo half-life in the bloodstream of 28 min after intravenous (i.v.) and 156 min after subcutaneous (s.c.) administrations in conscious normotensive rats. …”
  10. 43450

    Image2_LIT01-196, a Metabolically Stable Apelin-17 Analog, Normalizes Blood Pressure in Hypertensive DOCA-Salt Rats via a NO Synthase-dependent Mechanism.pdf by Adrien Flahault (2602345)

    Published 2021
    “…LIT01-196 behaves as a potent full agonist for the apelin receptor and has an in vivo half-life in the bloodstream of 28 min after intravenous (i.v.) and 156 min after subcutaneous (s.c.) administrations in conscious normotensive rats. …”
  11. 43451
  12. 43452

    Image_2_Identification of Sorafenib as a Treatment for Type 1 Diabetes.tif by Qin Zeng (166641)

    Published 2022
    “…Since sorafenib is classified as an FDA-approved drug, it serves as a preliminary lead point for additional experimentation and may be a promising therapy for type 1 diabetes in humans.…”
  13. 43453

    Illustration of three simple scenarios of association between genotype and a bivariate phenotype. by Matthew Stephens (3815)

    Published 2013
    “…A) A variant associated with <i>weight</i> but not <i>height</i>. …”
  14. 43454

    Image_1_Identification of Sorafenib as a Treatment for Type 1 Diabetes.tif by Qin Zeng (166641)

    Published 2022
    “…Since sorafenib is classified as an FDA-approved drug, it serves as a preliminary lead point for additional experimentation and may be a promising therapy for type 1 diabetes in humans.…”
  15. 43455

    Inc exhibits key properties of a Cul3 adaptor in neurons in vivo. by Qiuling Li (390393)

    Published 2025
    “…<p><b>(A)</b> Co-immunoprecipitation of 3×FLAG-Inc and 3×FLAG-3×HA-Cul3 from male whole animal lysates. …”
  16. 43456

    Image_4_Identification of Sorafenib as a Treatment for Type 1 Diabetes.tif by Qin Zeng (166641)

    Published 2022
    “…Since sorafenib is classified as an FDA-approved drug, it serves as a preliminary lead point for additional experimentation and may be a promising therapy for type 1 diabetes in humans.…”
  17. 43457

    Associations between HbA1c levels and mortality and diabetes complications. by Haipeng Ma (6792266)

    Published 2025
    “…The risk increases steadily with increasing HbA1c levels, with no clear inflection point. D: RCS curves for CKD risk. …”
  18. 43458

    Image_6_Identification of Sorafenib as a Treatment for Type 1 Diabetes.tif by Qin Zeng (166641)

    Published 2022
    “…Since sorafenib is classified as an FDA-approved drug, it serves as a preliminary lead point for additional experimentation and may be a promising therapy for type 1 diabetes in humans.…”
  19. 43459

    Image_3_Identification of Sorafenib as a Treatment for Type 1 Diabetes.tif by Qin Zeng (166641)

    Published 2022
    “…Since sorafenib is classified as an FDA-approved drug, it serves as a preliminary lead point for additional experimentation and may be a promising therapy for type 1 diabetes in humans.…”
  20. 43460